Medtech company Naitive Technologies has received 510(k) clearance from the FDA for OsteoSight.
The company’s flagship product, OsteoSight analyzes X-rays of the hip and pelvis of patients 50 years and older to identify cases at risk for low bone mineral density, according to a Sept. 11 news release from Naitive Technologies.
The insights can help orthopedic physicians and practices intervene earlier, improving surgical planning and patient outcomes.
With the clearance, Naitive Technologies is advancing commercial partnerships to bring OsteoSight into orthopedic practices across the U.S., the release said.
